HIMS stock falls after adding Wegovy, Ozempic to platform

Hims (HIMS) stock slipped over 2% after adding Novo Nordisk's GLP-1 weight-loss drugs to its platform. Users can now access Wegovy and Ozempic in various forms through the app. Hims also launched a new membership program offering 24/7 health access. Meanwhile, shares of Novo Nordisk (NVO) rose nearly 2% following the news.